Suppr超能文献

长期存在的基于原代肝细胞的共培养可改善肝毒性预测。

Long-enduring primary hepatocyte-based co-cultures improve prediction of hepatotoxicity.

作者信息

Novik Eric I, Dwyer Jacquelyn, Morelli James K, Parekh Amit, Cho Cheul, Pludwinski Eitan, Shrirao Anil, Freedman Robert M, MacDonald James S, Jayyosi Zaid

机构信息

Hμrel Corporation, North Brunswick, NJ 08902, United States.

Preclinical Safety, Sanofi, Framingham, MA 01701, United States.

出版信息

Toxicol Appl Pharmacol. 2017 Dec 1;336:20-30. doi: 10.1016/j.taap.2017.09.013. Epub 2017 Sep 21.

Abstract

The failure of drug candidates during clinical trials and post-marketing withdrawal due to Drug Induced Liver Injury (DILI), results in significant late-stage attrition in the pharmaceutical industry. Animal studies have proven insufficient to definitively predict DILI in the clinic, therefore a variety of in vitro models are being tested in an effort to improve prediction of human hepatotoxicity. The model system described here consists of cryopreserved primary rat, dog or human hepatocytes co-cultured together with a fibroblast cell line, which aids in the hepatocytes' maintenance of more in vivo-like characteristics compared to traditional hepatic mono-cultures, including long term viability and retention of activity of cytochrome P450 isozymes. Cell viability was assessed by measurement of ATP following treatment with 29 compounds having known hepatotoxic liabilities. Hμrelrat™, Hμreldog™, and Hμrelhuman™ hepatic co-cultures were treated for 24h, or under repeat-dosing for 7 or 13days, and compared to rat and human hepatic mono-cultures following single-dose exposure for 24h. The results allowed for a comparison of cytotoxicity, species-specific responses and the effect of repeat compound exposure on the prediction of hepatotoxic potential in each model. Results show that the co-culture model had greater sensitivity compared to that of the hepatic mono-cultures. In addition, "time-based ratios" were determined by dividing the compounds' 24-hour TC/C values by TC/C values measured after dosing for either 7 or 13days. The results suggest that this approach may serve as a useful adjunct to traditional measurements of hepatotoxicity, improving the predictive value of early screening studies.

摘要

候选药物在临床试验期间失败以及上市后因药物性肝损伤(DILI)而撤市,导致制药行业后期出现大量淘汰情况。动物研究已证明不足以明确预测临床中的DILI,因此正在测试各种体外模型,以努力改善对人类肝毒性的预测。这里描述的模型系统由冷冻保存的原代大鼠、犬或人肝细胞与一种成纤维细胞系共同培养组成,与传统的肝脏单培养相比,这有助于肝细胞维持更类似体内的特征,包括长期活力和细胞色素P450同工酶活性的保留。在用29种已知有肝毒性的化合物处理后,通过测量ATP来评估细胞活力。对Hμrelrat™、Hμreldog™和Hμrelhuman™肝脏共培养物进行24小时处理,或重复给药7天或13天,并与大鼠和人肝脏单培养物单次给药24小时后的情况进行比较。结果可以比较各模型中的细胞毒性、物种特异性反应以及重复化合物暴露对肝毒性潜力预测的影响。结果表明,与肝脏单培养相比,共培养模型具有更高的敏感性。此外,“基于时间的比率”通过将化合物的24小时TC/C值除以给药7天或13天后测量的TC/C值来确定。结果表明,这种方法可能作为传统肝毒性测量的有用辅助手段,提高早期筛查研究的预测价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验